BIO-key International, Inc. Q1 2026 Earnings Recap

BIO-key's stock was unchanged following its Q1 2026 earnings release, reflecting a market verdict that results and guidance were broadly in line with expectations despite ongoing operational challenges.

Key Takeaways

• Revenues benefited from new customer wins and expanded deployments in defense and financial services markets.
• Continued international expansion with regional partnerships in EMEA, India, and Vietnam supporting future growth prospects.
• Partnership with TD Synnex’s DLT Solutions aims to simplify public sector procurement in the U.S., targeting zero trust and multifactor authentication mandates.
• Business remains predominantly subscription-based with approximately 50% of new business sourced domestically via partners and 100% internationally through channel partners.
• Company is optimistic on growth and financial position, with $7.6 million in book value including over $2 million in cash, while shares remain suspended from NASDAQ pending an appeal hearing in June.